Log In
BCIQ
Print this Print this
 

Hex-hR1

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionFc fusion antibody comprising 6 Fab fragments of hR1, a humanized mAb against IGF1R, generated via the dock and lock (DNL) method
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationRenal cancer
Indication DetailsTreat renal cell carcinoma (RCC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today